What are the major opportunities in the Antiobesity market? What are the strategies for the Antiobesity market?

For detailed insights on the major opportunities and strategies in the Antiobesity market, Read More

How does the Antiobesity market relate to the overall economy and other similar markets?

For detailed insights on Antiobesity's relation to the overall economy and other similar markets, Read More

What are the latest mergers and acquisitions in the Antiobesity industry?

For detailed insights on the mergers and acquisitions in the Antiobesity industry, Read More

What are the key dynamics influencing the Antiobesity market growth? SWOT analysis of the Antiobesity market.

For detailed insights on the key dynamics influencing the Antiobesity market growth and SWOT analysis of the Antiobesity industry, Read More

Report Price : $4490.00

Pages : 175

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report

Antiobesity Global Market Report 2025

Name: Antiobesity Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drug Class (Peripherally acting anti obesity drugs, Centrally acting anti obesity drugs), By Type (Prescription Drugs (Rx), OTC Drugs), By Medication (Monotherapies, Polytherapies) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Antiobesity Market Overview

• Antiobesity market size has reached to $3.74 billion in 2024

• Expected to grow to $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%

• Growth Driver: Rising Prevalence Rate Of Obesity In The Anti-Obesity Drugs Market

• Market Trend: Product Innovations In The Anti-Obesity Drug Market

• North America was the largest region in 2024 and Middle East is the fastest growing region.

What Is Covered Under Antiobesity Market?

The anti-obesity drugs refer to the medications that are used to lower or regulate weight of a patient. These drugs interfere with one of the body's basic functions, controlling weight, by affecting either appetite or calorie absorption. Dieting (a healthy diet and caloric restriction) and exercise continue to be the main therapeutic approaches for overweight and obese people.

The main classes of drugs in anti-obesity are peripherally acting anti-obesity drugs and centrally acting anti-obesity drugs. Antiobesity medications with a peripheral effect help people lose weight without influencing the brain or decreasing their appetite. It blocks pancreatic lipase and hinders fat breakdown in the gastrointestinal tract, lowering fat absorption through the intestine. The different types of drugs include prescription drugs (Rx), and OTC drugs and involve various medications such as monotherapies and polytherapy.

What Is The Antiobesity Market Size 2025 And Growth Rate?

The antiobesity market size has grown rapidly in recent years. It will grow from $3.74 billion in 2024 to $4.1 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing obesity prevalence, awareness and education, lifestyle changes, government initiatives.

What Is The Antiobesity Market Growth Forecast?

The antiobesity market size is expected to see rapid growth in the next few years. It will grow to $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to market expansion, globalization. Major trends in the forecast period include research and development, patient-centric approaches, insurance coverage, technological advancements, digital health and telemedicine, novel drug therapies, bariatric surgery advancements, otc (over-the-counter) solutions, behavioral interventions, nutritional and weight management apps.

The forecast of 9.7% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. endocrinology clinics by driving up costs of glucagon-like peptide-1 receptor agonists like semaglutide sourced from Denmark and Singapore, exacerbating obesity management expenses and increasing metabolic disorder treatment burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Antiobesity Market Segmented?

1) By Drug Class: Peripherally Acting Anti-Obesity Drugs, Centrally Acting Anti-Obesity Drugs

2) By Type: Prescription Drugs (Rx), OTC Drugs

3) By Medication: Monotherapies, Polytherapies

Subsegments:

1) By Peripherally Acting Anti-Obesity Drugs: orlistat, Lorcaserin

2) By Centrally Acting Anti-Obesity Drugs: Phentermine, Topiramate, Naltrexone-Bupropion Combination, liraglutide

What Is Driving The Antiobesity Market? Rising Prevalence Rate Of Obesity In The Anti-Obesity Drugs Market

Obesity is a major public health concern globally. Globally, the prevalence rate of obesity is increasing every year. For instance, in May 2022, according to the World Obesity Atlas, a UK-based obesity organization, globally, it is estimated that more than 1 billion people will be suffering from obesity by 2030. This can be attributed to increased consumption of processed and unhealthy food, lack of physical activity, and lack of awareness of the risks of obesity. As a result, the demand for anti-obesity drugs is bound to increase in the future thus, driving the market growth.

What Is Driving The Antiobesity Market? Rising Geriatric Population

The rising geriatric population is expected to propel the growth of the anti obesity drugs market going forward. The geriatric population refers to the segment of the elderly or older, typically aged 65 and older. Anti-obesity drugs are a common and significant concern within the senior population. Elderly individuals with diabetes are particularly susceptible to obesity due to less body movement, reduced proper circulation of blood throughout the body. For instance, in October 2022, according to reports shared by the World Health Organization, a US-based specialized health agency, globally, 1 in 6 individuals will be 60 or older by 2030, and by 2050, there will be a double number of individuals in this age group (2.1 billion). Therefore, the rising geriatric population is driving the growth of the anti-obesity drugs market.

Who Are The Major Players In The Global Antiobesity Market?

Major companies operating in the antiobesity market include F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.

What Are The Key Trends Of The Global Antiobesity Market? Product Innovations In The Anti-Obesity Drug Market

Major companies operating in the anti-obesity drugs market are focusing on innovating new products, such as Mounjaro (tirzepatide), to provide reliable services to customers. Mounjaro (tirzepatide) is used as an anti-obesity drug for the treatment of adults with obesity or overweight with weight-related comorbidities. For instance, in October 2022, Eli Lilly and Company,a US-based pharmaceutical company, launched Mounjaro (tirzepatide), approved by the Food and Drug Administration (FDA), a US-based federal agency, as a fast track designation treatment. Mounjaro (tirzepatide) is an injectable form of anti-obesity drug used to help individuals struggling with obesity achieve their weight loss goals. This is used for adults with type 2 diabetes, along with diet and exercise, to improve blood sugar (glucose).

What Are The Key Trends Of The Global Antiobesity Market? Strategic Collaborations In The Anti-Obesity Drug Market

The pharmaceutical industry is witnessing an increase in the number of mergers and acquisitions among companies developing drugs for metabolic disorders such as obesity, diabetes, and others. This is a strategy of pharmaceutical companies to strengthen their drug portfolio in metabolic diseases and launch safe and effective drugs in the market. For instance, Evotec AG and Novo Nordisk entered into a strategic alliance to able to discover and develop drug molecules to treat metabolic disorders including obesity, diabetes, and other associated disorders.

Need data on a specific region in this market?

Request Customisation

Regional Outlook For The Global Antiobesity Market

North America was the largest region in the anti-obesity market in 2024. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Antiobesity Market?

The anti-obesity market consists of sales of liraglutide, semaglutide, naltrexone-bupropion, and orlistat. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Antiobesity Industry?

The antiobesity market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antiobesity industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Antiobesity Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$4.1 billion
Revenue Forecast In 2034	$5.94 billion
Growth Rate	CAGR of 9.7% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Drug Class: Peripherally Acting Anti-Obesity Drugs, Centrally Acting Anti-Obesity Drugs 2) By Type: Prescription Drugs (Rx), OTC Drugs 3) By Medication: Monotherapies, Polytherapies Subsegments: 1) By Peripherally Acting Anti-Obesity Drugs: Orlistat, Lorcaserin 2) By Centrally Acting Anti-Obesity Drugs: Phentermine, Topiramate, Naltrexone-Bupropion Combination, Liraglutide
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options
Market Size Value In 2025	$4.1 billion
Revenue Forecast In 2034	$5.94 billion
Growth Rate	CAGR of 9.7% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Drug Class: Peripherally Acting Anti-Obesity Drugs, Centrally Acting Anti-Obesity Drugs 2) By Type: Prescription Drugs (Rx), OTC Drugs 3) By Medication: Monotherapies, Polytherapies Subsegments: 1) By Peripherally Acting Anti-Obesity Drugs: Orlistat, Lorcaserin 2) By Centrally Acting Anti-Obesity Drugs: Phentermine, Topiramate, Naltrexone-Bupropion Combination, Liraglutide
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Antiobesity Market Characteristics

3. Antiobesity Market Trends And Strategies

4. Antiobesity Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Antiobesity Growth Analysis And Strategic Analysis Framework

5.1. Global Antiobesity PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Antiobesity Market Growth Rate Analysis

5.4. Global Antiobesity Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Antiobesity Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Antiobesity Total Addressable Market (TAM)

6. Antiobesity Market Segmentation

6.1. Global Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Peripherally Acting Anti-Obesity Drugs

Centrally Acting Anti-Obesity Drugs

6.2. Global Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Prescription Drugs (Rx)

OTC Drugs

6.3. Global Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monotherapies

Polytherapies

6.4. Global Antiobesity Market, Sub-Segmentation Of Peripherally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Orlistat

Lorcaserin

6.5. Global Antiobesity Market, Sub-Segmentation Of Centrally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Phentermine

Topiramate

Naltrexone-Bupropion Combination

Liraglutide

7. Antiobesity Market Regional And Country Analysis

7.1. Global Antiobesity Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Antiobesity Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antiobesity Market

8.1. Asia-Pacific Antiobesity Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antiobesity Market

9.1. China Antiobesity Market Overview

9.2. China Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antiobesity Market

10.1. India Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antiobesity Market

11.1. Japan Antiobesity Market Overview

11.2. Japan Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antiobesity Market

12.1. Australia Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antiobesity Market

13.1. Indonesia Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antiobesity Market

14.1. South Korea Antiobesity Market Overview

14.2. South Korea Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antiobesity Market

15.1. Western Europe Antiobesity Market Overview

15.2. Western Europe Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antiobesity Market

16.1. UK Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antiobesity Market

17.1. Germany Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antiobesity Market

18.1. France Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antiobesity Market

19.1. Italy Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antiobesity Market

20.1. Spain Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antiobesity Market

21.1. Eastern Europe Antiobesity Market Overview

21.2. Eastern Europe Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antiobesity Market

22.1. Russia Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antiobesity Market

23.1. North America Antiobesity Market Overview

23.2. North America Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antiobesity Market

24.1. USA Antiobesity Market Overview

24.2. USA Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antiobesity Market

25.1. Canada Antiobesity Market Overview

25.2. Canada Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antiobesity Market

26.1. South America Antiobesity Market Overview

26.2. South America Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antiobesity Market

27.1. Brazil Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antiobesity Market

28.1. Middle East Antiobesity Market Overview

28.2. Middle East Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antiobesity Market

29.1. Africa Antiobesity Market Overview

29.2. Africa Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antiobesity Market Competitive Landscape And Company Profiles

30.1. Antiobesity Market Competitive Landscape

30.2. Antiobesity Market Company Profiles

30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Antiobesity Market Other Major And Innovative Companies

31.1. Takeda Pharmaceutical Company Limited

31.2. Eisai Co. Ltd.

31.3. Novo Nordisk A/S

31.4. Zafgen Inc.

31.5. Rhythm Pharmaceuticals Inc.

31.6. Zydus Cadila

31.7. Norgine B.V.

31.8. Vivus Inc.

31.9. Arena Pharmaceuticals Inc.

31.10. Orexigen Therapeutics Inc.

31.11. Eli Lilly and Company

31.12. Amgen Inc.

31.13. AstraZeneca PLC

31.14. Novartis International AG

31.15. Viking Therapeutics Inc.

32. Global Antiobesity Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antiobesity Market

34. Recent Developments In The Antiobesity Market

35. Antiobesity Market High Potential Countries, Segments and Strategies

35.1 Antiobesity Market In 2029 - Countries Offering Most New Opportunities

35.2 Antiobesity Market In 2029 - Segments Offering Most New Opportunities

35.3 Antiobesity Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Antiobesity Market, Sub-Segmentation Of Peripherally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Antiobesity Market, Sub-Segmentation Of Centrally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Antiobesity Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Antiobesity Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Asia-Pacific, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Asia-Pacific, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: China, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: China, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: India, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: India, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: Japan, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: Japan, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Australia, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Australia, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Indonesia, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Indonesia, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: South Korea, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: South Korea, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Western Europe, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Western Europe, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: UK, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: UK, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Germany, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Germany, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: France, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: France, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Italy, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Italy, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Spain, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Spain, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Eastern Europe, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Eastern Europe, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Russia, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Russia, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: North America, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: North America, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: USA, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: USA, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: Canada, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: Canada, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: South America, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: South America, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Brazil, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Brazil, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Middle East, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Middle East, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Africa, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Africa, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: F. Hoffmann-La Roche AG Financial Performance

Table 77: GlaxoSmithKline plc Financial Performance

Table 78: Boehringer Ingelheim GmbH Financial Performance

Table 79: Pfizer Inc. Financial Performance

Table 80: Merck & Co. Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Antiobesity Market, Sub-Segmentation Of Peripherally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Antiobesity Market, Sub-Segmentation Of Centrally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Antiobesity Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Antiobesity Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Asia-Pacific, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Asia-Pacific, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: China, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: China, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: India, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: India, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: Japan, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: Japan, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Australia, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Australia, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Indonesia, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Indonesia, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: South Korea, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: South Korea, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Western Europe, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Western Europe, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: UK, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: UK, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Germany, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Germany, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: France, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: France, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Italy, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Italy, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Spain, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Spain, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Eastern Europe, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Eastern Europe, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Russia, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Russia, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: North America, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: North America, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: USA, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: USA, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: Canada, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: Canada, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: South America, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: South America, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Brazil, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Brazil, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Middle East, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Middle East, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Africa, Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Africa, Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: F. Hoffmann-La Roche AG Financial Performance

Figure 77: GlaxoSmithKline plc Financial Performance

Figure 78: Boehringer Ingelheim GmbH Financial Performance

Figure 79: Pfizer Inc. Financial Performance

Figure 80: Merck & Co. Inc. Financial Performance

Antiobesity Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Emerging Trends Redefining the Antiobesity Market Landscape: Innovative Advancements In The Anti-Parkinson Drugs Market

Top Trends Driving Innovation and Change in the Anti-Thyroid Drugs Market: Raising Awareness And Promoting Thyroid Health In The Anti-Thyroid Drug Market

Market Trends Influencing Strategic Decisions in the Antivirals Industry: Innovative Oral Antiviral Treatments Enhancing Patient Compliance And Accessibility In The Fight Against Viral Infections

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Antiobesity Global Market Report 2025 – By Drug Class (Peripherally acting anti obesity drugs, Centrally acting anti obesity drugs), By Type (Prescription Drugs (Rx), OTC Drugs), By Medication (Monotherapies, Polytherapi...

View Report

Antimony Global Market Report 2025 - By Type (Antimony Trioxide, Antimony Pentoxide, Alloys, Metal Ingots, Other Types), By Application (Flame retardant, Plastic additives, Lead acid batteries, Glass & ceramics, Other Ap...

View Report

Fresh Compressed Yeast Global Market Report 2025 – By Product Type (Baker’s Yeast, Brewer’s Yeast, Bio-ethanol Yeast, Feed Yeast), By Form (Fresh Yeast, Active Dry Yeast, Instant Yeast, Other Forms), By Application (Func...

View Report

Anticoagulants Global Market Report 2025 – By Drug Class (Factor Xa Inhibitor, Heparin And LMWH, Vitamin K Antagonist, Other Drug Classes), By Route Of Administration (Oral Anticoagulant, Injectable Anticoagulant), By Di...

View Report

Geotourism Global Market Report 2025 – By Tour Type (Individual Travel, Professional Groups, Group Travels), By Tourism Type (Sustainable Tourism, Urban Geo-Tourism, Rural Geo-Tourism, Natural Tourism, Eco Geo-Tourism, O...

View Report

Blockchain In Retail Global Market Report 2025 – By Component (Platform/Solutions, Services), By Providers (Application Providers, Middleware Providers, Infrastructure Providers), By Application (Compliance Management, I...

View Report

Bifurcation Lesions Global Market Report 2025 – By Types (One-Stent, Two-Stent), By Application (Coronary Vascular, Peripheral Vascular) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–...

View Report

Artificial Lift System Global Market Report 2025 – By Type (ESP, PCP, Gas Lift, Rod lift, Other Types), By Mechanism (Pump Assisted, Gas Assisted), By Application (Onshore, Offshore), By Well Type (Horizontal, Vertical) ...

View Report

Frequently Asked Questions

What is the definition of the Antiobesity market?

How will the Antiobesity market drivers and restraints affect the market dynamics? What forces will shape the Antiobesity industry going forward?

The market major growth driver - Rising Prevalence Rate Of Obesity In The Anti-Obesity Drugs Market. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Antiobesity market?

The antiobesity market size has grown strongly in recent years. It will grow from $3.74 billion in 2024 to $4.1 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing obesity prevalence, awareness and education, lifestyle changes, government initiatives. The antiobesity market size is expected to see strong growth in the next few years. It will grow to " $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to market expansion, globalization. Major trends in the forecast period include research and development, patient-centric approaches, insurance coverage, technological advancements, digital health and telemedicine, novel drug therapies, bariatric surgery advancements, otc (over-the-counter) solutions, behavioral interventions, nutritional and weight management apps. For further insights on this market, request a sample here

How is the Antiobesity market segmented?

The antiobesity market covered in this report is segmented –
1) By Drug Class: Peripherally Acting Anti-Obesity Drugs, Centrally Acting Anti-Obesity Drugs
2) By Type: Prescription Drugs (Rx), OTC Drugs
3) By Medication: Monotherapies, Polytherapies Subsegments:
1) By Peripherally Acting Anti-Obesity Drugs: Orlistat, Lorcaserin
2) By Centrally Acting Anti-Obesity Drugs: Phentermine, Topiramate, Naltrexone-Bupropion Combination, Liraglutide For further insights on this market, request a sample here

Which region has the largest share of the Antiobesity market? What are the other regions covered in the report?

North America was the largest region in the anti-obesity market in 2024. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Who are the major players in the Antiobesity market?

What are the key trends in the Antiobesity market?

Major trends in this market include Product Innovations In The Anti-Obesity Drug Market. For further insights on this market, request a sample here.

Book your 30 minutes free consultation with our research experts

Antiobesity Global Market Report 2025

By Drug Class (Peripherally acting anti obesity drugs, Centrally acting anti obesity drugs), By Type (Prescription Drugs (Rx), OTC Drugs), By Medication (Monotherapies, Polytherapies) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Antiobesity Market Overview

What Is Covered Under Antiobesity Market?

What Is The Antiobesity Market Size 2025 And Growth Rate?

What Is The Antiobesity Market Growth Forecast?

What’s The Trade War Impact On Pharmaceuticals Industry?

How Is The Antiobesity Market Segmented?

What Is Driving The Antiobesity Market? Rising Prevalence Rate Of Obesity In The Anti-Obesity Drugs Market

What Is Driving The Antiobesity Market? Rising Geriatric Population

Who Are The Major Players In The Global Antiobesity Market?

What Are The Key Trends Of The Global Antiobesity Market? Product Innovations In The Anti-Obesity Drug Market

What Are The Key Trends Of The Global Antiobesity Market? Strategic Collaborations In The Anti-Obesity Drug Market

Regional Outlook For The Global Antiobesity Market

What Defines the Antiobesity Market?

How is Market Value Defined and Measured?

What is the Market Assessment and Strategic Outlook for the Antiobesity Industry?

Antiobesity Market Report Forecast Analysis

Table Of Contents

List Of Tables

List Of Figures

Frequently Asked Questions